β2-microglobulin (B2M) is a non-glycosylated protein synthesized by nucleated cells. It is involved in the regulation of cancer cell growth and cancer bone metastasis, and also mediates cancer-related cell signaling networks. B2M is manifested in an increased concentration in body fluids in a variety of cancers and is a biomarker that can be used to indicate the prognosis and treatment effect of these cancers. Creative BioMart Biomarker provides customers with accurate, sensitive and specific cancer biomarker testing services, including B2M detection services. High-quality services, short turnaround time and reasonable prices can effectively help customers shorten the research cycle and reduce research costs.
B2M and Cancers
B2M is a 12kDa small molecular weight protein synthesized by all nucleated cells. B2M is the light chain part of the major histocompatibility complex (MHC) class I antigen that exists on the surface of nucleated cells, and is the key to the efficient transport of the newly born MHC class I heavy chain to the cell surface. MHC class I consist of a long 45kDa heavy chain, a short light chain and a transmembrane domain with a short cytoplasmic domain. it is responsible for presenting endogenous Antigen and activate CD8+ T cells. The binding of B2M to the heavy chain domain is essential to maintain the stability of MHC. MHC class I molecules are expressed on the cell surface. When MHC degrades, the membrane-bound heavy chain is endocytically internalized, and the monomeric B2M is released into the circulatory system. B2M is involved in multiple physiological mechanisms of the body, including immune mechanisms, as well as regulatory mechanisms for cell survival, proliferation, metastasis, and apoptosis. B2M is considered to be a regulator of cancer cell survival and metastasis in solid tumors. It is an active molecule that can stimulate cancer cell growth and angiogenesis, as well as promote epithelial-to-mesenchymal transition (EMT) and bone metastasis. Under normal physiological conditions, the content of B2M in blood and urine is low, while the concentration of B2M is increased in malignant diseases such as solid tumors, lymphomas and multiple myeloma, which indicates the synthesis and release of B2M in these malignant diseases increase. Therefore, B2M has the potential as a cancer biomarker, which may have an indicator effect on the prognosis and treatment effect of cancer patients.
Figure 1. Schematic diagram of B2M functions in cancer cells (Nomura, et al. 2014)
Application of B2M Detection
Plasma and serum B2M levels can be used as biomarkers in researches related to multiple myeloma, lymphoid malignancies, breast cancer, renal cell carcinoma, prostate cancer, etc.
Our Advantages
- Guarantee high accuracy and sensitivity for B2M detection
- Ensure high repeatability of B2M detection
- Short turn-around time of detection service
- Competitive price in the market of B2M detection services
- Multiple technology platforms for B2M test services (ELISA, ECL)
- Accept a wide range of sample types (plasma, serum, cell culture supernatants, etc.)
Workflow of Biomarker Detection at Creative BioMart Biomarker
Creative BioMart Biomarker strictly controls each specific experimental step in the detection procedure to ensure accurately quantify the level of B2M in each sample.
At Creative BioMart Biomarker, we offer high-quality B2M detection service that ensuring the sensitivity and specificity of test results. You can also talk to our experts according to your certain requirement, and we will determine the final detection scheme based on the communication results. Please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.
Reference:
- Nomura, T.; et al. β2-microglobulin-mediated signaling as a target for cancer therapy. Anti-Cancer Agents in Medicinal Chemistry. 2014, 14(3): 343-352.
